Coulie Bernard 4

What Happened
Coulie Bernard, President & CEO and a director of Pliant Therapeutics (PLRX), sold 89,375 shares of common stock in a disposition totaling approximately $114,400. The reported weighted-average sale price was $1.28 per share (sales ranged from $1.245 to $1.33). This was a sale (not a purchase or exercise).

Key Details

• Transaction date: primary report date 2026-01-20; filing date 2026-01-22 (Form 4 filed timely).
• Transaction type/code: Sale (S). Shares disposed: 89,375. Weighted-average price reported: $1.28; broker sales ranged $1.245–$1.33 (Jan 20–22, 2026).
• Purpose/footnote: Footnote F1 states this was a nondiscretionary sale under a Rule 10b5-1 arrangement by the plan to satisfy tax withholding on vested restricted stock units for a group of employees (including Bernard). The reporting person will provide a per-price breakdown of shares sold on request.
• Other footnotes: F2 notes 1,959 shares were acquired under an Employee Stock Purchase Plan; F3 indicates additional shares held by The Coulie/Leyman Family Trust (Bernard and spouse are trustees) and he disclaims beneficial ownership except to the extent of pecuniary interest.
• Shares owned after transaction: not specified in the filing.

Context
The sale was executed to cover tax withholding tied to RSU vesting and was processed through a pre-arranged (10b5-1) mechanism—common for insider tax-related dispositions. Such transactions are typically routine and do not by themselves indicate a change in insider sentiment.